Ferreira Adriana Aparecida, Leite Isabel Cristina Gonçalves, Duncan Natalie August
Universidade Federal de Juiz de Fora UFJF, Juiz de Fora, MG, Brazil; Fundação Centro de Hematologia e Hemoterapia de Minas Gerais Hemominas, Juiz de Fora, MG, Brazil.
Universidade Federal de Juiz de Fora UFJF, Juiz de Fora, MG, Brazil.
Hematol Transfus Cell Ther. 2018 Jan-Mar;40(1):18-24. doi: 10.1016/j.bjhh.2017.09.002. Epub 2017 Nov 26.
Prophylaxis is the treatment of choice for patients with severe hemophilia. Low adherence may limit the effectiveness of the prophylactic regimen, thereby compromising outcomes.
The objective of this study was to validate the Brazilian version of the VERITAS-Pro prophylaxis adherence scale, originally an American questionnaire that can be answered by the individual responsible for prophylaxis as well as by an observer.
The scale has 24 questions divided into six subscales: Routine, Dosage, Plan, Remember, Skip and Communicate. Participants were recruited at a blood center in southeastern Brazil for validation and reliability analyses. Validation measures included the results obtained using analog visual scales of adherence, interval between medication dispensed by the treatment center pharmacy and the percentage of recommended doses administered and infusions registered in the patients' logs.
The study included 32 individuals responsible for prophylaxis and five observers. The internal consistency was very good for the VERITAS-Pro total score, excellent for the Remember, Skip and Communicate subscales, good for the Dosage subscale, and acceptable for the Routine and Plan subscales. Twelve participants answered the questionnaire on more than one occasion to evaluate reproducibility. The intraclass correlation coefficient was excellent. Regarding convergent validity, the VERITAS-Pro scores were moderately correlated with the global adherence scale and with infusion log records, but showed a weak correlation with pharmacy dispensation records.
The Brazilian version of VERITAS-Pro is a valid and reliable instrument, enabling the understanding of specific factors related to non-adherence and allowing targeted interventions for proper treatment.
预防治疗是重度血友病患者的首选治疗方法。依从性低可能会限制预防治疗方案的有效性，从而影响治疗效果。
本研究的目的是验证VERITAS-Pro预防依从性量表的巴西版本，该量表最初是一份美国问卷，负责预防治疗的个人以及观察者均可作答。
该量表有24个问题，分为六个子量表：常规、剂量、计划、记忆、漏用和沟通。研究对象在巴西东南部的一个血液中心招募，进行效度和信度分析。效度测量包括使用依从性模拟视觉量表获得的结果、治疗中心药房配药间隔时间以及患者日志中记录的推荐剂量给药百分比和输注情况。
该研究纳入了32名负责预防治疗的人员和5名观察者。VERITAS-Pro总分的内部一致性非常好，记忆、漏用和沟通子量表的内部一致性极佳，剂量子量表的内部一致性良好，常规和计划子量表的内部一致性可接受。12名参与者多次回答问卷以评估可重复性。组内相关系数极佳。关于收敛效度，VERITAS-Pro得分与总体依从性量表和输注日志记录呈中度相关，但与药房配药记录的相关性较弱。
VERITAS-Pro的巴西版本是一种有效且可靠的工具，有助于了解与不依从相关的具体因素，并允许进行有针对性的干预以实现恰当治疗。
